Innate Pharma is a clinical-stage biotechnology company developing immunotherapies for cancer by harnessing the innate immune system through three proprietary platforms: monoclonal antibodies targeting specific immune pathways, the ANKET® platform that activates natural killer cells to attack tumors, and antibody drug conjugates delivering targeted cytotoxic payloads. The company operates primarily through partnerships and licensing agreements with large pharmaceutical companies such as AstraZeneca and Sanofi, generating revenue through upfront payments, clinical and regulatory milestone payments, royalties on future product sales, government research financing, and cost-sharing arrangements. As a pre-commercialization biotech company, Innate maintains a portfolio of clinical and preclinical oncology candidates and depends on achieving regulatory approvals, completing clinical trials successfully, generating milestone payments from existing collaborations, and securing additional financing through new partnerships or capital markets access to sustain operations and advance its development pipeline.